Friday, December 2, 2011
Auxilium Pharmaceuticals Inc., of Malvern, Pa., said the first patient was dosed in its Phase IIa trial of Xiaflex (collagenase clostridium histolyticum) in idiopathic adhesive capsulitis of the shoulder, also known as frozen shoulder syndrome. The trial is expected to enroll about 50 adults and will assess the drug's safety and efficacy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.